Erlotinib hydrochloride Basic information

Product Name:	Erlotinib hydrochloride
Synonyms:	ERLOTINIB HCL;ERLOTINIB HCL SALT;ERLOTINIB HCL SALT :TARCEVA;Erlotinib, Hydrochloride Salt;N-(3-Ethynylphenyl)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine, Hydrochloride Salt, OSI 774, Tarceva;N-(3-Ethynylphenyl)-6,7-bis-(2-methoxyethoxy)-quinazolin-4-amine;[6,7-Bis-(2-methoxy-ethoxy)-quinazolin-4yl]-(3-ethynyl-phenyl)-amine;Tarceva HydrochlorideSee E625000
CAS No:	183319-69-9
MF:	C22H24ClN3O4
MW:	429.9
EINECS:	620-491-0

Erlotinib hydrochloride Chemical Properties

Melting point	223-225°C
Boiling point	553.6ºC at 760mmHg
storage temp.	Inert atmosphere,Store in freezer, under -20°C
solubility	Soluble in DMSO (up to 18 mg/ml with warming).
pka	pKa (25°): 5.42
form	Yellow powder.
color	White or off-white
Stability:	Stable for 1 year from date of purchase as supplied. Solutions in DMSO may be stored at -20° for up to 3 months.

Erlotinib hydrochloride Usage And Synthesis

Chemical Properties	Off-White Solid
Originator	Pfizer(US)
Uses	Erlotinib hydrochloride (V), a quinazoline derived small molecule inhibitor of epidermal growth factor receptor (EDGFR) tyrosine kinase, was approved in November, 2004, for the treatment of advanced or metastatic non-smallcell lung cancer. It belongs to the same class as gefitinib,another quinazoline approved for treatment of advanced lung cancer, but with improved pharmacokinetic properties. The molecule was originated by Pfizer and development initiated in collaboration with OSI, which assumed full rights to the drug when Pfizer merged with Warner Lambert. Subsequently, Genentech/Roche went into licensing agreement with OSI to develop and market the drug in the US and Worldwide.

It is the hydrochloride of the molecularly targeted drug erlotinib. The U.S. Food and Drug Administration (FDA) has approved erlotinib (Tarceva) combined with gemcitabine as the first-line treatment for locally advanced and metastatic pancreatic cancer. The small molecule compound erlotinib is a receptor tyrosine kinase inhibitor. It inhibits the phosphorylation reaction by competitively binding with adenosine triphosphate to the catalytic site of the receptor tyrosine kinase in the cell, thereby blocking the It has proliferation signal transduction, inhibits the activity of tumor cell ligand-dependent HER-1/EGFR, and achieves the effect of inhibiting tumor cell proliferation. It is also another tyrosine kinase inhibitor used in the treatment of NSCLC.

Hot Tags: erlotinib hydrochloride cas no.183319-69-9, China, manufacturers, suppliers, factory, custom, wholesale, Atazanavir Intermediates, Lenalidomide, CAS NO 191732 72 6

Erlotinib Hydrochloride CAS NO.183319-69-9

You Might Also Like

Send Inquiry